Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Thomas Filleron"'
Autor:
Nathalie Andrieu-Abadie, Muriel Mounier, Pascale Olivier, Thierry Levade, Mathieu Virazels, Jean Milhès, Carine Dufau, Maha Ayyoub, Bruno Ségui, Cécile Pagès, Amélie Lusque, Jean-Pierre Delord, Stéphanie Brayer, Céline Colacios, Thomas Filleron, Anne Montfort, Nicolas Meyer
Publikováno v:
Clinical Cancer Research. 27:1037-1047
Purpose: TNF blockers can be used to manage gastrointestinal inflammatory side effects following nivolumab and/or ipilimumab treatment in patients with advanced melanoma. Our preclinical data showed that anti-TNF could promote the efficacy of immune
Autor:
Isabelle Rouquette, Thomas Filleron, Gilles Favre, Anne Casanova, Julien Mazieres, Olivier Calvayrac, Isabelle Raymond-Letron, Michèle Beau-Faller, Valérie Lauwers-Cances, Emilie Bousquet, Jacques Cadranel, Julie Milia, Anne Pradines
Publikováno v:
Clinical Cancer Research
Clinical Cancer Research, American Association for Cancer Research, 2014, 20 (24), pp.6541-6550. ⟨10.1158/1078-0432.CCR-14-0506⟩
Clinical Cancer Research, American Association for Cancer Research, 2014, 20 (24), pp.6541-6550. ⟨10.1158/1078-0432.CCR-14-0506⟩
Purpose: A crucial event in lung adenocarcinoma progression is the switch from an aerogenous spread toward an infiltrating tumor. Loss of RhoB expression has been suggested to be critical for lung cancer invasion. Here, we tested RhoB expression as a
Autor:
Henri Roché, Gilles Favre, Odile Schiltz, Bernard Monsarrat, Emilie Malissein, Karima Chaoui, Ben Allal, Florence Dalenc, Sabrina Marsili, Valérie Lauwers-Cances, Elise Meunier, Sophie F. Doisneau-Sixou, Nicole Renée, Thomas Filleron
Publikováno v:
Clinical Cancer Research. 16:1264-1271
Purpose: Tipifarnib, a farnesyltransferase inhibitor, has antitumor activity in heavily pretreated metastatic breast cancer patients. Preclinical data suggest that FTIs could restore tamoxifen responsiveness in tamoxifen-resistant disease. Thus, comb
Autor:
Vincent Minville, Véronique Minard, Claire Illac, Jean-Marc Guinebretière, Natacha Entz-Werle, Françoise Rédini, Béatrice Marie, Marta Jimenez, Anne Gomez-Brouchet, Frédérique Larousserie, Corinne Bouvier, Laurence Brugières, François Gouin, Sophie Piperno-Neumann, Sébastien Aubert, Gonzague de Pinieux, Julia Gilhodes, Thomas Filleron, Eric Mascard, Marie-cecile Ledeley
Publikováno v:
Clinical Cancer Research. 24:B29-B29
The French phase 3 trial (OS 2006) testing combining zoledronate (an osteoclast inhibitor) with chemotherapy and surgery did not improve the outcome of patients with osteosarcoma. To understand this unexpected result, the presence of infiltrating imm